Medscape is available in 5 Language Editions – Choose your Edition here.


Hyperthyroidism, Thyroid Storm, and Graves Disease Medication

  • Author: Erik D Schraga, MD; Chief Editor: Romesh Khardori, MD, PhD, FACP  more...
Updated: May 29, 2014

Medication Summary

The goals of medical therapy are blockade of peripheral effects, inhibition of hormone synthesis, blockade of hormone release, and prevention of peripheral conversion of T4 to T3. Restoration of a clinical euthyroid state may take up to 8 weeks.

Blocking agents such as beta-blockers reduce sympathetic hyperactivity and decrease peripheral conversion of T4 to T3.

Guanethidine and reserpine have been used to provide sympathetic blockade and may be effective agents if beta-blockers are contraindicated or not tolerated.

Iodides and lithium work to block release of preformed thyroid hormone.

Thionamides prevent synthesis of new thyroid hormone.


Inhibitors of hormone synthesis

Class Summary

Thionamides (eg, propylthiouracil, methimazole) prevent hormone synthesis by inhibiting both the organification of iodine to tyrosine residues and the coupling of iodotyrosines. The drug must be given orally or via a nasogastric tube. PTU has the added benefit of inhibiting peripheral conversion of T4 to T3.

Propylthiouracil (PTU)


DOC; effects may be seen soon after drug is started, but therapy may need to be continued for 4-12 wk. Laboratory monitoring of T4 and T3 levels may be required to adjust therapy. Although classified as pregnancy category D, recommended as DOC for women who are pregnant or breastfeeding.

Methimazole (Tapazole)


An effective inhibitor of thyroid synthesis; however, it does not inhibit peripheral conversion of thyroid hormone


Blockade of hormone release

Class Summary

Iodides and lithium are used effectively to block the release of thyroid hormone. Effects are exerted directly on the thyroid gland. Lithium is used only as a secondary agent due to difficulty in titrating to an effective dose and its narrow therapeutic window. These agents should be administered at least 1 hour after PTU is given to ensure the advance blockade of thyroid hormone formation; otherwise, administering iodides could worsen symptoms. Iodide preparations are known to cause serum sickness–type reactions. Iodides should not be used for long-term therapy in thyrotoxicosis. Preparations include saturated solution of potassium iodide (SSKI), iopanoic acid, and Lugol iodine.

Iopanoic acid


Absorption from GI tract is rapid and complete. Iodine equilibrates in extracellular fluids and is concentrated specifically by thyroid gland. For treatment of thyrotoxicosis, parenteral iodine may be used.

Saturated solution of potassium iodide (SSKI, PIMA)


Inhibits thyroid hormone secretion. Solution contains 50 mg of iodide per drop and may be mixed with juice or water.

Lugol solution


Inhibits thyroid hormone secretion. Contains 8 mg of iodide per drop. May be mixed with juice or water for intake.


Beta-adrenergic blockers

Class Summary

Beta-blockade is mainstay of symptomatic therapy; antiadrenergic effects block effects of excess thyroid hormone. Beta-blockade also plays a role in the prevention of peripheral conversion of T4 to T3. Propranolol is the best studied in this class, but other beta-blockers have similar effects in hyperthyroidism.

Effects are relatively dramatic, and results may be seen within 10 minutes after administration.

Use of beta-blockers improves heart failure that is due to thyrotoxic tachycardia or thyrotoxic myocardial depression but may worsen heart failure that is due to other causes. When in doubt, therapy may be begun with a short-acting titratable agent, such as esmolol.

Reserpine and guanethidine are effective autonomic blockers that may be used if beta-blockers are contraindicated.

Propranolol (Inderal)


DOC; can control cardiac and psychomotor manifestations within minutes.



Class Summary

These agents play a role in the prevention of peripheral conversion of T4 to T3

Dexamethasone (Decadron)


Blocks conversion of T4 to T3 and does not interfere with cortisol stimulation testing.

Contributor Information and Disclosures

Erik D Schraga, MD Staff Physician, Department of Emergency Medicine, Mills-Peninsula Emergency Medical Associates

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Howard A Bessen, MD Professor of Medicine, Department of Emergency Medicine, University of California, Los Angeles, David Geffen School of Medicine; Program Director, Harbor-UCLA Medical Center

Howard A Bessen, MD is a member of the following medical societies: American College of Emergency Physicians

Disclosure: Nothing to disclose.

Chief Editor

Romesh Khardori, MD, PhD, FACP Professor of Endocrinology, Director of Training Program, Division of Endocrinology, Diabetes and Metabolism, Strelitz Diabetes and Endocrine Disorders Institute, Department of Internal Medicine, Eastern Virginia Medical School

Romesh Khardori, MD, PhD, FACP is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians, American Diabetes Association, Endocrine Society

Disclosure: Nothing to disclose.

Additional Contributors

Robin R Hemphill, MD, MPH Associate Professor, Director, Quality and Safety, Department of Emergency Medicine, Emory University School of Medicine

Robin R Hemphill, MD, MPH is a member of the following medical societies: American College of Emergency Physicians, Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

  1. Williamson S, Greene SA. Incidence of thyrotoxicosis in childhood: a national population based study in the UK and Ireland. Clin Endocrinol (Oxf). 2010 Mar. 72(3):358-63. [Medline].

  2. Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst. 2011 Nov 2. 103(21):1572-87. [Medline]. [Full Text].

  3. FDA MedWatch Safety Alerts for Human Medical Products. Propylthiouracil (PTU). US Food and Drug Administration. Available at Accessed: June 3, 2009.

  4. Kreisner E, Lutzky M, Gross JL. Charcoal hemoperfusion in the treatment of levothyroxine intoxication. Thyroid. Feb 2010. 20(2):209-12. [Medline].

  5. Vyas AA, Vyas P, Fillipon NL, Vijayakrishnan R, Trivedi N. Successful treatment of thyroid storm with plasmapheresis in a patient with methimazole-induced agranulocytosis. Endocr Pract. 2010 Jul-Aug. 16(4):673-6. [Medline].

  6. Alfadhli E, Gianoukakis AG. Management of severe thyrotoxicosis when the gastrointestinal tract is compromised. Thyroid. 2011 Mar. 21(3):215-20. [Medline].

  7. Chong HW, See KC, Phua J. Thyroid storm with multiorgan failure. Thyroid. Mar 2010. 20(3):333-6. [Medline].

  8. Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med. 2005 Jul. 118(7):706-14. [Medline].

  9. Braverman LE, Utiger RD. Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text. 7th ed. 1996.

  10. Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am. 1993 Jun. 22(2):263-77. [Medline].

  11. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000 Feb 28. 160(4):526-34. [Medline].

  12. Cappola AR, Fried LP, Arnold AM, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006 Mar 1. 295(9):1033-41. [Medline].

  13. Carlson HE. Gynecomastia. N Engl J Med. 1980 Oct 2. 303(14):795-9. [Medline].

  14. Cooper DS. Antithyroid drugs. N Engl J Med. Mar 2005. 352(9):905-17. [Medline].

  15. Fisher JN. Management of thyrotoxicosis. South Med J. 2002 May. 95(5):493-505. [Medline].

  16. Gharib H. Changing concepts in the diagnosis and management of thyroid nodules. Endocrinol Metab Clin North Am. 1997 Dec. 26(4):777-800. [Medline].

  17. Glauser J, Strange GR. Hypothyroidism and hyperthyroidism in the elderly. Emerg Med Rep. 2002. 1(2):1-12.

  18. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002 Feb. 87(2):489-99. [Medline].

  19. Kudrjavcev T. Neurologic complications of thyroid dysfunction. Adv Neurol. 1978. 19:619-36. [Medline].

  20. McKeown NJ, Tews MC, Gossain VV, Shah SM. Hyperthyroidism. Emerg Med Clin North Am. 2005 Aug. 23(3):669-85, viii. [Medline].

  21. Pimentel L, Hansen KN. Thyroid disease in the emergency department: a clinical and laboratory review. J Emerg Med. 2005 Feb. 28(2):201-9. [Medline].

  22. Ragland E, Urbanic RC. Thyroid emergencies. Harwood-Nuss Al, Linden CH, eds. The Clinical Practice of Emergency Medicine. 2nd ed. Lippincott Williams & Wilkins; 1996. 736-41.

  23. Ragland G. Thyroid storm. Emergency Medicine: A Comprehensive Study Guide. 4th ed. New York, NY: McGraw-Hill; 1996. 736-9.

  24. Ringel MD. Management of hypothyroidism and hyperthyroidism in the intensive care unit. Crit Care Clin. 2001 Jan. 17(1):59-74. [Medline].

  25. Rozien MF. Anesthetic implications of concurrent diseases. Anesthesia. Churchill Livingstone; 1994. 926-8.

  26. Rozien MF, Fleisher LA. Essence of Anesthesia Practice. WB Saunders Co; 1997. 177.

  27. Scott SK. Thyroid disorders. Markovchick VJ, Pons PT, Wolfe RE, eds. Emergency Medicine Secrets. Hanley and Belfus; 1993. 178-82.

  28. Sniezek JC, Francis TB. Inflammatory thyroid disorders. Otolaryngol Clin North Am. 2003 Feb. 36(1):55-71. [Medline].

  29. Streetman DD, Khanderia U. Diagnosis and treatment of Graves disease. Ann Pharmacother. 2003 Jul-Aug. 37(7-8):1100-9. [Medline].

  30. Tietgens ST, Leinung MC. Thyroid storm. Med Clin North Am. 1995 Jan. 79(1):169-84. [Medline].

  31. Waldstein SS, Slodki SJ, Kaganiec GL. A clinical study of thyroid storm. Ann Intern Med. 1960. 52:626-42.

  32. Warofsky L, Ingbar SH. Diseases of the thyroid. Wilson JD, Brunwald E, et al, eds. Harrison's Principles of Internal Medicine. McGraw-Hill; 1991. 1692-1712.

  33. Weetman AP. Graves' disease. N Engl J Med. 2000 Oct 26. 343(17):1236-48. [Medline].

  34. Wogan JM. Endocrine disorders. Rosen P, Barkin RM, et al, eds. Emergency Medicine: Concepts and Clinical Practice. Mosby-Year Book; 1992. 2242-59.

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.